How much statistical sleight of hand can you spot in this paragraph on the new CDC website, which is now littered with muddled and flawed claims about vaccines and autism? www.cdc.gov/vaccine-safe... 🧵
Curious about our work?
You can read more about our experiences setting up the group: blogs.imperial.ac.uk/imperial-med... blogs.imperial.ac.uk/imperial-med...
Proud of our work supporting LGBTQIA+ scientists conducting international research! 🌍🏳️🌈 Whether you're part of the community or an ally, explore the resources and support we've put together here 👉 www.imperial.ac.uk/school-publi...
Curious about our work?
We shared our experiences in these blog posts: blogs.imperial.ac.uk/imperial-med... blogs.imperial.ac.uk/imperial-med...
Ipswich looking glorious in the sun. Brilliant 48h with the @pducambridge.bsky.social solving the pressing questions in infectious diseases, competing in penalty shoot outs and cooking up a storm #PDURetreat
Our work helped inform WHO policy on dengue vaccines—supporting the strategic use of Qdenga where it can do the most good. Huge thanks to my PhD supervisors Ilaria Dorigatti & Neil Ferguson for the opportunity and their support on this project!
Key findings:
1. Protection varies by serostatus & serotype
2. Cannot rule out an enhanced disease risk for seronegatives infected with serotypes 3 and 4, esp in children <6 years
3. Targeted Qdenga rollout (>6 yrs in high transmission settings) could still reduce hospitalisation burden by up to 20%
We built a Bayesian model linking antibody titres to protection-by—serotype, age & serostatus—and embedded it in a transmission model to evaluate real-world impact across settings.
Our new paper is out in @natmed.nature.com! We modelled the efficacy & public-health impact of the new Takeda #dengue vaccine (Qdenga), combining trial data with transmission models to guide optimal #vaccine use: rdcu.be/etk3h. 🧵👇
